Use of 3D-CT-derived psoas major muscle volume in defining sarcopenia in colorectal cancer.
3-dimensional computed tomography
Colorectal cancer
Psoas major muscle volume
Sarcopenia
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
07
12
2023
accepted:
14
06
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
18
6
2024
Statut:
epublish
Résumé
Sarcopenia is characterized by reduced skeletal muscle volume and is a condition that is prevalent among elderly patients and associated with poor prognosis as a comorbidity in malignancies. Given the aging population over 80 years old in Japan, an understanding of malignancies, including colorectal cancer (CRC), complicated by sarcopenia is increasingly important. Therefore, the focus of this study is on a novel and practical diagnostic approach of assessment of psoas major muscle volume (PV) using 3-dimensional computed tomography (3D-CT) in diagnosis of sarcopenia in patients with CRC. The subjects were 150 patients aged ≥ 80 years with CRC who underwent primary tumor resection at Juntendo University Hospital between 2004 and 2017. 3D-CT measurement of PV and conventional CT measurement of the psoas major muscle cross-sectional area (PA) were used to identify sarcopenia (group S) and non-sarcopenia (group nS) cases. Clinicopathological characteristics, operative results, postoperative complications, and prognosis were compared between these groups. The S:nS ratios were 15:135 for the PV method and 52:98 for the PA method. There was a strong positive correlation (r = 0.66, p < 0.01) between PVI (psoas major muscle volume index) and PAI (psoas major muscle cross-sectional area index), which were calculated by dividing PV or PA by the square of height. Surgical results and postoperative complications did not differ significantly in the S and nS groups defined using each method. Overall survival was worse in group S compared to group nS identified by PV (p < 0.01), but not significantly different in groups S and nS identified by PA (p = 0.77). A Cox proportional hazards model for OS identified group S by PV as an independent predictor of a poor prognosis (p < 0.05), whereas group S by PA was not a predictor of prognosis (p = 0.60). The PV method for identifying sarcopenia in elderly patients with CRC is more practical and sensitive for prediction of a poor prognosis compared to the conventional method.
Sections du résumé
BACKGROUND
BACKGROUND
Sarcopenia is characterized by reduced skeletal muscle volume and is a condition that is prevalent among elderly patients and associated with poor prognosis as a comorbidity in malignancies. Given the aging population over 80 years old in Japan, an understanding of malignancies, including colorectal cancer (CRC), complicated by sarcopenia is increasingly important. Therefore, the focus of this study is on a novel and practical diagnostic approach of assessment of psoas major muscle volume (PV) using 3-dimensional computed tomography (3D-CT) in diagnosis of sarcopenia in patients with CRC.
METHODS
METHODS
The subjects were 150 patients aged ≥ 80 years with CRC who underwent primary tumor resection at Juntendo University Hospital between 2004 and 2017. 3D-CT measurement of PV and conventional CT measurement of the psoas major muscle cross-sectional area (PA) were used to identify sarcopenia (group S) and non-sarcopenia (group nS) cases. Clinicopathological characteristics, operative results, postoperative complications, and prognosis were compared between these groups.
RESULTS
RESULTS
The S:nS ratios were 15:135 for the PV method and 52:98 for the PA method. There was a strong positive correlation (r = 0.66, p < 0.01) between PVI (psoas major muscle volume index) and PAI (psoas major muscle cross-sectional area index), which were calculated by dividing PV or PA by the square of height. Surgical results and postoperative complications did not differ significantly in the S and nS groups defined using each method. Overall survival was worse in group S compared to group nS identified by PV (p < 0.01), but not significantly different in groups S and nS identified by PA (p = 0.77). A Cox proportional hazards model for OS identified group S by PV as an independent predictor of a poor prognosis (p < 0.05), whereas group S by PA was not a predictor of prognosis (p = 0.60).
CONCLUSIONS
CONCLUSIONS
The PV method for identifying sarcopenia in elderly patients with CRC is more practical and sensitive for prediction of a poor prognosis compared to the conventional method.
Identifiants
pubmed: 38890682
doi: 10.1186/s12885-024-12524-y
pii: 10.1186/s12885-024-12524-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
741Informations de copyright
© 2024. The Author(s).
Références
Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990S–S991.
doi: 10.1093/jn/127.5.990S
pubmed: 9164280
Sun Q, Jiang X, Qin R, et al. Sarcopenia among older patients with cancer: A scoping review of the literature. J Geriatr Oncol. 2022;13:924–34.
doi: 10.1016/j.jgo.2022.03.008
pubmed: 35644850
Surov A, Wienke A. Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients. JPEN J Parenter Enteral Nutr. 2022;46(8):1761–8.
doi: 10.1002/jpen.2415
pubmed: 35633306
Surov A, Strobel A, Borggrefe J, Wienke A. Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis. Eur Radiol. 2023;33(9):6426–37.
doi: 10.1007/s00330-023-09524-0
pubmed: 36929392
Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, Wienke A. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis Clin Nutr. 2021;40(10):5298–310.
pubmed: 34536638
Trejo-Avila M, Bozada-Gutiérrez K, Valenzuela-Salazar C, Herrera-Esquivel J, Moreno-Portillo M. Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36(6):1077–96.
doi: 10.1007/s00384-021-03839-4
pubmed: 33481108
Meyer HJ, Strobel A, Wienke A, Surov A. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis. Clin Colorectal Cancer. 2022;21(3):e213–25.
doi: 10.1016/j.clcc.2022.03.005
pubmed: 35792019
National Cancer Center: https://ganjoho.jp/reg_stat/statistics/stat/summary.html . Accessed 23 Nov 2023.
Vergara-Fernandez O, Trejo-Avila M, Salgado-Nesme N. Sarcopenia in patients with colorectal cancer: A comprehensive review. World J Clin Cases. 2020;8:1188–202.
doi: 10.12998/wjcc.v8.i7.1188
pubmed: 32337193
pmcid: 7176615
Hirayama K. The measurement of the psoas major muscle volume by 3 dimensional-CT for assessment of nutritional state. J Jpn Soc Parenteral Enteral Nutr. 2017;32:871–7.
Brierley J, Gospodarowicz M, Wittekind C. UICC TNM classification of malignant tumours. 8th ed. Chichester: Wiley; 2017.
Japan Society of Hepatology: https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/sarcopenia.html Accessed 23 Nov 2023.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Hashiguchi Y, Muro K, Saito Y, et al. Japanese society for cancer of the colon and rectum. japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.
doi: 10.1007/s10147-019-01485-z
pubmed: 31203527
Takahashi M, Niitsu H, Sakamoto K, et al.: Japan Society of Laparoscopic Colorectal Surgery. Survival benefit of lymph node dissection in surgery for colon cancer in elderly patients: A multicenter propensity score-matched study in Japan. Asian J Endosc Surg. 2018;11:346–54.
doi: 10.1111/ases.12474
pubmed: 29601663
Merchant RA, Seetharaman S, Au L, et al. Relationship of fat mass index and fat free mass index with body mass index and association with function, cognition and sarcopenia in pre-frail older adults. Front Endocrinol (Lausanne). 2021;12:765415.
doi: 10.3389/fendo.2021.765415
pubmed: 35002957
World Health Organization HP. https://apps.who.int/gho/data/view.main.SDG2016LEXv?lang=en . Accessed 23 Nov 2023.
Cabinet Office HP: https://www8.cao.go.jp/kourei/whitepaper/w-2022/html/zenbun/s1_1_1.html . Accessed 23 Nov 2023.
Williams GR, Rier HN, McDonald A, et al. Sarcopenia and aging in cancer. J Geriatr Oncol. 2019;10:374–7.
doi: 10.1016/j.jgo.2018.10.009
pubmed: 30343999
Xia L, Zhao R, Wan Q, et al. Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies. Cancer Med. 2020;9:7964–78.
doi: 10.1002/cam4.3428
pubmed: 32924316
pmcid: 7643685
Nipp RD, Fuchs G, El-Jawahri A, et al. Sarcopenia is associated with quality of life and depression in patients with advanced cancer. Oncologist. 2018;23:97–104.
doi: 10.1634/theoncologist.2017-0255
pubmed: 28935775
Takiguchi K, Furuya S, Sudo M, et al. Prognostic effect of sarcopenia in colorectal cancer recurrence. Nutrition. 2021;91–92:111362.
doi: 10.1016/j.nut.2021.111362
pubmed: 34274653
Tagliafico AS, Bignotti B, Torri L, et al. Sarcopenia: how to measure, when and why. Radiol Med. 2022;127:228–37.
doi: 10.1007/s11547-022-01450-3
pubmed: 35041137
pmcid: 8960583
Di Vincenzo O, Marra M, Di Gregorio A, et al. Bioelectrical impedance analysis (BIA)-derived phase angle in sarcopenia: A systematic review. Clin Nutr. 2021;40:3052–61.
doi: 10.1016/j.clnu.2020.10.048
pubmed: 33183880
Pickhardt PJ, Perez AA, Garrett JW, et al. Fully automated deep learning tool for sarcopenia assessment on ct: l1 versus l3 vertebral level muscle measurements for opportunistic prediction of adverse clinical outcomes. AJR Am J Roentgenol. 2022;218:124–31.
doi: 10.2214/AJR.21.26486
pubmed: 34406056
Horie K, Matsuda T, Yamashita K, et al. Sarcopenia assessed by skeletal muscle mass volume is a prognostic factor for oncological outcomes of rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by surgery. Eur J Surg Oncol. 2022;48:850–6.
doi: 10.1016/j.ejso.2021.10.018
pubmed: 34756762
Yamada Y, Shimada Y, Makino Y, et al. Clinical utility of psoas muscle volume in assessment of sarcopenia in patients with early-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2023;149:3277–85.
doi: 10.1007/s00432-022-04234-4
pubmed: 35916994
Manabe T, Ogawa C, Takuma K, et al. Usefulness of the measurement of psoas muscle volume for sarcopenia diagnosis in patients with liver disease. Diagnostics (Basel). 2023;13:1245.
doi: 10.3390/diagnostics13071245
pubmed: 37046463
So SP, Lee BS, Kim JW. Psoas muscle volume as an opportunistic diagnostic tool to assess sarcopenia in patients with hip fractures: A retrospective cohort study. J Pers Med. 2021;11:1338.
doi: 10.3390/jpm11121338
pubmed: 34945811
pmcid: 8709037
Womer AL, Brady JT, Kalisz K, et al. Do psoas muscle area and volume correlate with postoperative complications in patients undergoing rectal cancer resection? Am J Surg. 2018;215:503–6.
doi: 10.1016/j.amjsurg.2017.10.052
pubmed: 29277239
Kim SE, Paik HY, Yoon H, et al. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015;21:5167–75.
doi: 10.3748/wjg.v21.i17.5167
pubmed: 25954090
pmcid: 4419057
Nelke C, Dziewas R, Minnerup J, et al. Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine. 2019;49:381–8.
doi: 10.1016/j.ebiom.2019.10.034
pubmed: 31662290
pmcid: 6945275
Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457–65.
doi: 10.1038/nrendo.2012.49
pubmed: 22473333
Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33:74–82.
doi: 10.1200/JCO.2014.57.3329
pubmed: 25403209
Daitoku N, Miyamoto Y, Hiyoshi Y, et al. Preoperative skeletal muscle status is associated with tumor-infiltrating lymphocytes and prognosis in patients with colorectal cancer. Ann Gastroenterol Surg. 2022;6:658–66.
doi: 10.1002/ags3.12570
pubmed: 36091309
pmcid: 9444852
Kim M, Lee SM, Son IT, Park T, Oh BY. Prognostic Value of Artificial Intelligence-Driven, Computed Tomography-Based, Volumetric Assessment of the Volume and Density of Muscle in Patients With Colon Cancer. Korean J Radiol. 2023;24(9):849–59.
doi: 10.3348/kjr.2023.0109
pubmed: 37634640
pmcid: 10462901
Dohzono S, Sasaoka R, Takamatsu K, Hoshino M, Nakamura H. Prognostic value of paravertebral muscle density in patients with spinal metastases from gastrointestinal cancer. Support Care Cancer. 2019;27(4):1207–13.
doi: 10.1007/s00520-018-4465-x
pubmed: 30220027
Yao H, Dohzono S, Sasaoka R, Takamatsu K, Nakamura H. Prognostic value of psoas major muscle density in patients with breast cancer metastases to bone: a retrospective single-center cohort study. Jpn J Clin Oncol. 2022;52(1):8–13.
doi: 10.1093/jjco/hyab166
pubmed: 34642753
Cuijpers ACM, Bongers BC, Heldens AFJM, Bours MJL, van Meeteren NLU, Stassen LPS, Lubbers T. Aerobic fitness and muscle density play a vital role in postoperative complications in colorectal cancer surgery. J Surg Oncol. 2022;125(6):1013–23.
doi: 10.1002/jso.26817
pubmed: 35147981
pmcid: 9305785
van der Zanden V, van Soolingen NJ, Viddeleer AR, Trum JW, Amant F, Mourits MJE, Portielje JEA, van den Bos F, de Kroon CD, Kagie MJ, Oei SA, Baalbergen A, van Haaften-de Jong ALD, Houtsma D, van Munster BC, Souwer ETD. Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer. Gynecol Oncol. 2021;162(2):360–7.
doi: 10.1016/j.ygyno.2021.05.039
pubmed: 34112514
Kurokawa Y. How can sarcopenia be prevented after gastrointestinal surgery? Ann Gastroenterol Surg. 2022;6:604–5.
doi: 10.1002/ags3.12617
pubmed: 36091313
pmcid: 9444864
Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21:300–7.e2.
doi: 10.1016/j.jamda.2019.12.012
pubmed: 32033882
Cruz-Jentoft AJ, Bahat G, Bauer J, et al.: Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
doi: 10.1093/ageing/afy169
pubmed: 30312372